ReviewThe Journal of pharmacology and experimental therapeutics2025
ProSAAS neuropeptides and receptors GPR171 and GPR83: Potential therapeutic applications for pain, anxiety, and body weight regulation.
Review in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Profiling Endogenous Opioid Peptide Release from Adrenal Chromaffin Cells.ACS chemical neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptides derived from the precursor named proSAAS are some of the most abundant peptides present in the brain, with levels comparable to enkephalin, neuropeptide Y, and several other well-studied neuropeptides. Despite their abundance, the proSAAS-derived peptides are not well-known by the scientific community. In the ∼25 years since their discovery, much has been learned about the role of several of these peptides and their receptors, with functions including energy balance and body weight regulation, fear, anxiety, reward behavior, and pain. This review provides an overview of this emerging field and outlines important areas for further studies. SIGNIFICANCE STATEMENT: Neuropeptides perform important roles in cellular signaling and their receptors are the targets of hundreds of distinct pharmacotherapies. The peptides derived from proSAAS are highly abundant and broadly expressed in the brain, and their receptors represent an emerging target for novel therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.